-
1.发明授权Pharmaceutical composition for treating or preventing cancer by inducing dendritic cell-like differentiation from monocytes to improve anticancer immune activity 有权通过从单核细胞诱导树突状细胞样分化来治疗或预防癌症以提高抗癌免疫活性的药物组合物公开(公告)号：US08614093B2
公开(公告)日：2013-12-24
申请号：US12934394
申请日：2009-03-24
申请人： Hiromi Kumon , Yasutomo Nasu , Masami Watanabe , Yuji Kashiwakura
发明人： Hiromi Kumon , Yasutomo Nasu , Masami Watanabe , Yuji Kashiwakura
CPC分类号： A61K38/18 , A61K38/00 , C07K14/4703 , C07K14/4747 , C12N5/0639 , C12N2501/22 , C12N2501/2304 , C12N2501/415
摘要： According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided.Specifically, the following is provided: an agent for activating cancer immunity, which comprises, as an active ingredient, the following REIC protein: (a) a protein consisting of the amino acid sequence shown in SEQ ID NO: 2; or (b) a protein consisting of an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 2 by substitution, deletion, or addition of one or more amino acid(s) and having the activity of inducing differentiation from monocytes into dendritic cell-like cells.
摘要翻译： 根据本发明，提供了用于诱导或激活树突状细胞样细胞以通过免疫治疗来治疗或预防癌症的组合物。 具体而言，提供以下功能：用于激活癌症免疫的药剂，其包含作为活性成分的以下REIC蛋白质：（a）由SEQ ID NO：2所示的氨基酸序列组成的蛋白质; 或（b）通过取代，缺失或添加一个或多个氨基酸并且具有诱导从单核细胞分化的活性的由源自SEQ ID NO：2所示氨基酸序列的氨基酸序列组成的蛋白质 进入树突状细胞样细胞。
-
2.发明申请PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER BY INDUCING DENDRITIC CELL-LIKE DIFFERENTIATION FROM MONOCYTES TO IMPROVE ANTICANCER IMMUNE ACTIVITY 有权通过诱导单核细胞中的细胞样细胞分化来治疗或预防癌症的药物组合物，以提高抗体免疫活性公开(公告)号：US20120034251A1
公开(公告)日：2012-02-09
申请号：US12934394
申请日：2009-03-24
申请人： Hiromi Kumon , Yasutomo Nasu , Masami Watanabe , Yuji Kashiwakura
发明人： Hiromi Kumon , Yasutomo Nasu , Masami Watanabe , Yuji Kashiwakura
IPC分类号： A61K38/17 , A61K31/711 , A61P37/04 , C12N15/861 , C12N5/0784 , A61P35/00 , C12N5/0786 , C12N15/85
CPC分类号： A61K38/18 , A61K38/00 , C07K14/4703 , C07K14/4747 , C12N5/0639 , C12N2501/22 , C12N2501/2304 , C12N2501/415
摘要： According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided.Specifically, the following is provided: an agent for activating cancer immunity, which comprises, as an active ingredient, the following REIC protein: (a) a protein consisting of the amino acid sequence shown in SEQ ID NO: 2; or (b) a protein consisting of an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 2 by substitution, deletion, or addition of one or more amino acid(s) and having the activity of inducing differentiation from monocytes into dendritic cell-like cells.
摘要翻译： 根据本发明，提供了用于诱导或激活树突状细胞样细胞以通过免疫治疗来治疗或预防癌症的组合物。 具体而言，提供以下功能：用于激活癌症免疫的药剂，其包含作为活性成分的以下REIC蛋白质：（a）由SEQ ID NO：2所示的氨基酸序列组成的蛋白质; 或（b）通过取代，缺失或添加一个或多个氨基酸并且具有诱导从单核细胞分化的活性的由源自SEQ ID NO：2所示氨基酸序列的氨基酸序列组成的蛋白质 进入树突状细胞样细胞。
-
公开(公告)号：US08658612B2
公开(公告)日：2014-02-25
申请号：US13056443
申请日：2009-07-30
申请人： Hiromi Kumon , Yasutomo Nasu , Yuji Kashiwakura , Masami Watanabe , Nam-ho Huh , Masakiyo Sakaguchi
发明人： Hiromi Kumon , Yasutomo Nasu , Yuji Kashiwakura , Masami Watanabe , Nam-ho Huh , Masakiyo Sakaguchi
CPC分类号： C07K14/47 , A61K35/13 , A61K38/00 , C12N2799/022
摘要： A method for potentiating the antitumor immunity in an animal by administering REIC/Dkk-3, or a therapeutic agent for malignant mesothelioma containing REIC/Dkk-3, or a vector containing the DNA as an active ingredient; wherein the DNA consists of the nucleotide sequence shown in SEQ ID NO: 1; or (b) a DNA hybridizing under stringent conditions to the DNA consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 1 and encoding a protein having apoptosis-inducing activity and interleukin (IL-7) production-accelerating activity in cells.
摘要翻译： 通过施用REIC / Dkk-3或含有REIC / Dkk-3的恶性间皮瘤的治疗剂或含有该DNA作为活性成分的载体来增强动物的抗肿瘤免疫力的方法。 其中DNA由SEQ ID NO：1所示的核苷酸序列组成; 或（b）在严格条件下与由与SEQ ID NO：1所示核苷酸序列互补的核苷酸序列组成的DNA杂交并编码具有凋亡诱导活性和白细胞介素（IL-7）产生加速活性的蛋白质的DNA 在细胞中。
-
4.发明授权Cancer cell death inducing agent having effects of potentiating anticancer drug against anticancer-drug-resistant cancer 有权具有增强抗癌药物抗癌药物耐药性癌症作用的癌细胞死亡诱导剂公开(公告)号：US08946173B2
公开(公告)日：2015-02-03
申请号：US12734488
申请日：2008-11-05
IPC分类号： A61K48/00 , C12N15/00 , C12N15/86 , A61K31/713
CPC分类号： A61K31/713 , A61K48/00 , C12N2710/10043
摘要： The present invention provides a drug capable of causing cancer cells to restore anticancer drug sensitivity in cases in which cancer has acquired resistance to an anticancer drug and inducing cell death in cancer cells. The present invention specifically provides a cancer cell death inducing agent comprising REIC/Dkk-3 DNA as an active ingredient and having effects of potentiating an anticancer drug for cancer cells having anticancer drug resistance.
摘要翻译： 本发明提供了能够使癌细胞恢复抗癌药敏感性的药物，其中癌症已获得抗癌药物的抗性并诱导癌细胞中的细胞死亡。 本发明具体提供了包含REIC / Dkk-3 DNA作为活性成分的癌细胞死亡诱导剂，并具有增强抗癌药抗癌药物抗性的癌细胞的作用。
-
5.发明申请CANCER CELL DEATH INDUCING AGENT HAVING EFFECTS OF POTENTIATING ANTICANCER DRUG AGAINST ANTICANCER-DRUG-RESISTANT CANCER 有权癌症细胞死亡诱导剂对潜在抗药物药物的抗药性药物抗药性公开(公告)号：US20110269824A1
公开(公告)日：2011-11-03
申请号：US12734488
申请日：2008-11-05
IPC分类号： A61K31/7088 , C12N15/861 , A61P35/00 , C12N15/85
CPC分类号： A61K31/713 , A61K48/00 , C12N2710/10043
摘要： The present invention provides a drug capable of causing cancer cells to restore anticancer drug sensitivity in cases in which cancer has acquired resistance to an anticancer drug and inducing cell death in cancer cells. The present invention specifically provides a cancer cell death inducing agent comprising REIC/Dkk-3 DNA as an active ingredient and having effects of potentiating an anticancer drug for cancer cells having anticancer drug resistance.
摘要翻译： 本发明提供了能够使癌细胞恢复抗癌药敏感性的药物，其中癌症已获得抗癌药物的抗性并诱导癌细胞中的细胞死亡。 本发明具体提供了包含REIC / Dkk-3 DNA作为活性成分的癌细胞死亡诱导剂，并具有增强抗癌药抗癌药物抗性的癌细胞的作用。
-
公开(公告)号：US20110189237A1
公开(公告)日：2011-08-04
申请号：US13056443
申请日：2009-07-30
申请人： Hiromi Kumon , Yasutomo Nasu , Yuji Kashiwakura , Masami Watanabe , Nam-ho Huh , Masakiyo Sakaguchi
发明人： Hiromi Kumon , Yasutomo Nasu , Yuji Kashiwakura , Masami Watanabe , Nam-ho Huh , Masakiyo Sakaguchi
IPC分类号： A61K31/7088 , A61P35/00 , A61P37/04
CPC分类号： C07K14/47 , A61K35/13 , A61K38/00 , C12N2799/022
摘要： According to the present invention, a method for treating malignant mesothelioma using REIC/Dkk-3 and a therapeutic agent for malignant mesothelioma comprising REIC/Dkk-3 are provided. A mesothelioma therapeutic agent is provided, comprising the following REIC/Dkk-3 DNA or a vector comprising the DNA as an active ingredient: (a) a DNA consisting of the nucleotide sequence shown in SEQ ID NO: 1; or (b) a DNA hybridizing under stringent conditions to a DNA consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 1 and encoding a protein having apoptosis-inducing activity and IL-7 production-accelerating activity in cells.
摘要翻译： 根据本发明，提供了使用REIC / Dkk-3治疗恶性间皮瘤的方法和包含REIC / Dkk-3的恶性间皮瘤治疗剂。 提供间皮瘤治疗剂，其包含以下REIC / Dkk-3 DNA或包含该DNA作为活性成分的载体：（a）由SEQ ID NO：1所示核苷酸序列组成的DNA; 或（b）在严格条件下与由与SEQ ID NO：1所示核苷酸序列互补的核苷酸序列组成的DNA杂交并编码细胞中具有凋亡诱导活性和IL-7生产加速活性的蛋白质的DNA。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.011 秒)